Vivitra 150mg injection consist a targeted cancer drug known as Trastuzumab, which is Pharmacologically grouped as humanized monoclonal antibody produced by recombinant DNA technology

1. Vivitra 150mg injection
Vivitra 150mg injection consist a targeted cancer drug known as Trastuzumab,
which is Pharmacologically grouped as humanized monoclonal antibody produced
by recombinant DNA technology.
Vivitra 150mg helps to reduce the rate of reactivation & mortality.
One of the epidermal growth factor receptor is known as human epidermal growth
factor receptor 2 (HER2) plays vital role in breast cancer.
This factor is responsible for cell replication.
An FDA approved product Vivitra 150mg which is involved in breast cancer
treatment.
Vivitra 150mg vial with 858mg of lyophilized powder containing 150mg of
Trastuzumab
Indication
The drug Vivitra 150mg is indicated for the treatment of following conditions:
Supportive treatment for breast cancer
Advanced breast cancer
Advanced gastric cancer.
Dosage & Administration
Breast cancer Metastatic HER2-Overexpressing:
• Over a 90 minute, 4mg/kg alone or with combination of paclitaxel in initial
dose.
• Over 30 minutes, 2mg /kg once in a week for maintenance dose.
• Duration of therapy for initial and maintenance dose until disease
progression.
Adjuvant regimen for HER2 over expressing Breast cancer:

2. 52 weeks of treatment total schedules as follows:
• Combination With paclitaxel or docetaxel, overa 90 minute, 4mg/kg IV then
over 30 minutes, 2mg /kg for 12 weeks or combination with Carboplatin/ docetaxel
for 18 weeks one week following the last weekly dose.
• Over 30 to 90 minutes, 6mg/kg IV for every 3 weeks.
Esophageal carcinoma or gastric cancer for adult dose:
• 8mg/kg IV over 90 minutes as initial dose
• 6mg/kg IV over 30 to 90 minutes for every 3 weeks as maintenance dose
• Duration of therapy for initial and maintenance dose until disease
progression.
Administration:
Vivitra is administer into vein through IV infusion over 90 minutes
Do not administer IV push or bolus.
Duration of Vivitra is administratedin once every week or every 3 weeks.
Before starting treatment, patients should undergo biopsy to check Vivitra is the
right regimen the infusion solution should be compatible to polyvinyl chloride or
polyethylene bags.
After dilution, the infusion bag should be stored at 2oC to 8oC for not more than
24 hours before use.
Over dosage :
Maximum dose of Trastuzumab is more than 8mg/kg as a single dose.
In case of over dosage condition, patient must be;
Provide with supportive measures
Monitor the signs & symptoms due to over dosage .
Pharmacokinetic

3. Distribution:
Volume of distribution: 44 mL/kg as trastuzumab; 3.13 L as trastuzumab
emtansine.
Metabolism:
As trastuzumab emtansine: which Undergoes deconjugation and catabolism
through proteolysis in cellular lysosomes.
Excretion:
Terminal Elimination half-life is 6 days (weekly dosing); 16 days (3 weekly
regimen); approx 4 days as trastuzumab emtansine.
Elimination of drug includes clearance of IgG through the reticuloendothelial
system.
Mechanism
Vivitra 150mg is a type of monoclonal antibody which targeting the HER2,
provoke a resistant mediate reaction which causes disguise and down regulation of
HER2.
HER2 pathway is specific for cell proliferation, joining of Transtuzumab to the site
of HER2 causes prevention of this activity. This joining leads to antibody mediated
and leads to HER2 positive cells break down.
Vivitra 150mg is a intermediary of anti-body dependent cellular cytotoxicity.
Drug Interaction
Vivitra 150mg interaction with anthracycline after ending of Vivitra 150mg
treatment may have a chance of getting cardiac problem. This side effects occur
because of Transtuzumab great disaster period is depends on population PK
analysis.
Do not take anthracycline treatment for 7 months after stopping the Vivitra 150mg
treatment.

4. In some phenomenal condition, patient should get anthracycline, in that situation
patient’s cardiac function should be checked carefully with regular intervals.
Safety Precautions
Cardiomyopathy;
Vivitra 150mg receiving patients have increased risk of exposing to cardiac
disorders.
To overcome the problem by;
Monitoring cardiac functions regularly
Avoid using anthracycline drug after Vivitra 150mg treatment
Provide alternative therapy management
In serious condition, treatment should be discontinuing. Infusion reactions;
During Vivitra 150mg treatment some life-threatening infusion reactions are
produced.
The manifestation due to infusion reactions should be monitored frequently
Delay the infusion of Vivitra 150mg treatment and Start the supportive measures
by providing epinephrine, corticosteroids, diphenhydramine, bronchodilators, &
oxygen.
In serious infusion reactions, Stop the Vivitra 150mg treatment permanently.
Patient should be treated with premedication before starting the infusion to
overcome the such problem Embryo fetal damage;
Vivitra 150mg is contraindicated to pregnancy period.
Avoid becoming pregnancy during this therapy.
Use efficient contraceptives during treatment Pulmonary toxicity;
Some serious fatal cases of pulmonary toxicity occur during Vivitra 150mg
treatment.

5. During Vivitra 150mg treatment. Use with Caution. Therapy induced neutropenia;
Higher incidence of neutropenia occurs during Vivitra 150mg treatment.
Missed dose
If missed cycles of Vivitra 150mg treatment by one week or less, then the repeated
maintenance dose (weekly schedule: 2mg/kg; 3 weekly schedule: 6mg/kg)
administer as soon as probably.
Until the next planned cycle the patient does not take interval.
Consecutive Vivitra 150mg maintenance dose should be taken in 7 days or 21 days
next confer to the weekly or 3 weekly schedules. If patient missed to take Vivitra
150mg dose by higher than one week, then resume with re-storing dose of Vivitra
150mg such as weekly schedule is 4mg/kg; 3 weekly schedules is 8mg/kg should
be administered over period of 90 minutes.
Side Effects
The most common adverse effects;
Cardiomyopathy, Infusion reactions, Embryo fetal toxicity, Pulmonary toxicity,
Chemotherapy induced neutropenia. The most common side effects;
Hypertension, Influenza, Dyspnae, URI, Rhinitis, Pharyngolaryngeal pain,
Sinusitis, Epitasis, Pulmonary hypertension, Dizziness, Decrease LVEF,
Palpitations, Arrhythmia, Cardiac failure, Cough, Interstitial pneumonitis,
Diarrhea/constipation, Nausea, vomiting, Dyspepsia, Autoimmune thyroiditis,
Neutropenia, Hypokalemia, Anemia, Thrombocytopenia, Febrile neutropenia,
Renal failure, Abdominal pain, Arthralgia, Back pain, Bone pain, Headache,
Paresthesia, Rash,, Nail disorders, Pruritus, Pyrexia, Chills, Edema, Asthenia,
Sudden death.
Contact us
Email id :applepharmaceutical@gmail.com
Phone no : +91- 9987711567